Helsinn Birex Pharmaceuticals Ltd, Dublin (HBP)

In 2009, the Helsinn Group invested in a new Centre-of-Excellence for oral solid dosage forms and a stability center to support the development of a group of new solid dose products. In 2014, the first new product from this facility was approved by the FDA and launched on the US market. To date, in the region of CHF60million has been invested in the Dublin site, as well as the sites of its strategic contract-manufacturing partners, which provide more dedicated capacity. Together, these investments guarantee reliability of all elements of the supply chain both for development and commercial products.

Overview

  • Building area 8,000m2 on a site area of 27,100m2
  • Oral solid dosage forms, topical forms and packaging of sterile products
  • Worldwide logistic platform
  • Solid-dose development and clinical supply
  • Stability Center
  • Inspected and approved by HPRA on behalf of EMA and PICS and US FDA
  • Employment approximately 180 (2016)